State of Florida - Find Information on Disaster and Recovery
Make a Referral

Pharmaceutical Services are described by the National Home Infusion Association (NHIA) as an integral part of Home and Specialty Infusion. The Centers for Medicaid and Medicare Services (CMS) has additional guidelines outlining pharmacist’s responsibilities. IV Solutions RX highly trained pharmacists organize and coordinate the provision of complex specialty infusion medications that are provided in the outpatient setting for patients with complex, chronic disease. Typically, those medications are provided in the patient’s home or an infusion suite. The majority of these medications involve administration through a needle or catheter, otherwise known as infusion, while others are administered via alternate routes of administration such as intramuscular, epidural, and self-injectable means. Infusion medications are prescribed for both acute and chronic illnesses that cannot be effectively treated with oral medications alone.

Home Infusion and Specialty Infusion pharmacies are licensed pharmacies in one or multiple states. In our specific case, IV Solutions RX has pharmacy licenses in 49 states nationwide plus the District of Columbia. At IV Solutions RX, our specialty infusion services include medications such as IVIg (immune globulin), SCIg (subcutaneous immune globulin), clotting factor for bleeding disorders, and TNF-alpha blockers such as Remicade®, Inflectra®, Renflexis®, and Entyvio®.  These medications are used to treat a variety in complex diseases including CIDP (Chronic Inflammatory Demyelinating Polyneuropathy), MMN (Multifocal Motor Neuropathy, MG (Myasthenia Gravis),  immune deficiencies, various other neurological disorders, rheumatoid arthritis, Crohn’s disease, hemophilia, and many others. A recent NHIA study found that in 2019 home infusion and specialty providers cared for more than 3 million patients in the United States, representing a 300% increase since the last industry study in 2008.

High quality Pharmaceutical Services assures that Home and Specialty Infusion Services can be delivered safely and effectively as an alternative to inpatient care for a variety of therapies and disease states, both acute and chronic. For many patients, receiving treatment at home or in an infusion suite is preferable to inpatient care. This application of Pharmaceutical Services is continuing to grow now and into the future as more therapies are approved and quality outcomes are seen for home and specialty infusion patients. Providers help assure quality through accreditation processes using one or more of the many accrediting organizations (AOs) including The Joint Commission, ACHC, URAC, and more.

Thanks to the National Home Infusion Association www.nhia.org for providing parts of the overview described above.

Our Featured Products

IVIg & SCIg

Asceniv™
Bivigam®
Cutaquig®
Cuvitru™
Flebogamma®
Gammagard Liquid®
Gammagard S/D ®
Gammaked™
Gammaplex®
Gamunex®
Hizentra®
Hyqvia®
Octagam®
Panzyga®
Privigen®
Xembify®

TNF-alpha Blockers

  • Cimzia® (certolizumab)
  • Enbrel® biosimilars
    • Erelzi® (etanercept-szzs)
    • Eticovo® (etanercept-ykro)
  • Entyvio®  (vedolizumab)
  • Humira® biosimilars
    • Amjevitta® (adalimumab-atto)
    • Cyletezo® (adalimumab-adbm)
    • Hyrimoz® (adalimumab-adaz)
    • Hadlima® (adalimumab-bwwd)
    • Abrilad® a (adalimumab-afzb)
    • Huilo® (adalimumab-fkjp)
    • Yusimry® (adalimumab-aqvh)
  • Infliximab
  • Remicade® (infliximab) biosimilars
    • Renflexis® (infliximab-abda)
    • Inflectra® (infliximab-dyyb)
    • Ixifi®(infliximab-qbtx)
    • Avsola®(infliximab-axxq)
  • Simponi® (golimumab)
  • Simponi ARIA® (golimumab)

Additional Product Offerings

*Drug list available only by prescription from an appropriately licensed medical professional. Availability is subject to available drug supply and manufacturer contracts which may restrict authorized pharmacy sources. Changes in the available drug supply may result in drug shortages and can occur for many reasons. IV Solutions RX monitors these issues to adapt our patient’s care plans to the available drug supply.